Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

Inclusion Criteria : * Subject aged between 18 and 57 years (i.e., less than 60 at the last vaccination) * For woman of child-bearing potential, negative urine pregnancy test at V#01 * Use of effective contraception prior to and during the trial * Subject available during the trial period * Subject able to read and understand the informed consent form * Informed consent form signed and dated by the subject prior to any protocol-required intervention (and Visit 05 and Visit 07, respectively). Exclusion Criteria : * Self-reported allergy to egg proteins, chick proteins, or any of the constituents of the vaccine, in particular, neomycin, formaldehyde, and octoxinol 9 * Acute febrile disease within the 72 hours preceding V#01, or axillary temperature \>37.5°C the day of inclusion, prior to vaccination (\>37.0°C Czech Republic) * Subject with an aggravation of existing chronic illness (heart disease, respiratory disease, etc.) * Vaccination against influenza within the 6 months preceding V#01 * Any vaccination within the 28 days preceding V#01 or scheduled between V#01 and V#02 * Breast-feeding * Immunosuppressive therapy including long term systemic corticotherapy (20 mg/day of prednisolone or equivalent for \>2 weeks) or cancer therapy within the month preceding V#01 or ongoing * Immunoglobulin injection within the 3 months preceding V#01 * Subject taking part or planned to take part in another clinical trial (3 months before and through the trial duration) * Subject having received extracted pituitary hormones * Subjects who participated in the GID01 study (Lithuanian centers)